Strides Pharma Global, the wholly-owned subsidiary of Strides Shasun, has received final approval for Cinacalcet Hydrochloride tablets from the US FDA. Cinacalcet Hydrochloride tablets is a generic version of Sensipar tablets of Amgen, a US-based company. It is used for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis and other forms of thyroid. The product is part of the backward integrated formulations portfolio and will receive API supplies from Solara Active Pharma Sciences under a long-term manufacturing agreement. The product will be manufactured at the company’s oral dosage facility at Puducherry and will be marketed by Strides Pharma Inc in the US.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.